Please login to the form below

Not currently logged in
Email:
Password:

R&D news in brief

Our weekly round-up of news in brief

Acne drug linked to depression
Scientists at Bath University have drawn a link between Roche's drug for severe acne, Roaccutane, and depression. Writing in the journal, Neuropsychopharmacology, the team said they gave Roaccutane to adolescent mice over a six-week period, and monitored their behaviour. While the scientists found no change in the physical abilities of the mice, the creatures spent significantly more time immobile in a range of laboratory assessments designed to test their response to stress. ìEstablishing a link between the active molecules within the drug and a change in depression-related behaviour, albeit in mice, is an important step forward in our understanding of the effects of this drug in the wider context of brain function,î said researcher, Dr Sarah Bailey.

Avandia may prevent diabetes, says study
GSK's Avandia (rosiglitazone), in combination with diet and exercise, decreased the risk of high-risk patients developing type II diabetes by 62 per cent compared to placebo, according to the results of a DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) study. In one arm of the study, patients with pre-diabetes, or higher-than-normal blood glucose levels, were randomised to receive a once-daily dose of Avandia or placebo. After a median follow-up of three years, 280 patients taking Avandia developed diabetes, compared to 658 patients who took placebo. The findings also showed that 51 per cent of patients taking Avandia returned to normal blood glucose levels, compared with 30 per cent of those taking placebo.

Aclasta effective in fracture risk reduction
Novartis says clinical tests have shown its once-yearly medicine, Aclasta, had proved effective in reducing incidence of bone fracture in women with postmenopausal osteoporosis (PMO). Data from the phase III trials showed benefits across the most common fracture sites - hip, spine and non-spine - with the effects sustained over three years. Aclasta met the study's two primary endpoints as patients experienced a 70 per cent risk reduction in new spine fractures and a 40 per cent risk reduction in hip fractures, the company said. The drug also met all secondary endpoints, including risk reduction in clinical spine fractures and non-spine fractures.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...

Infographics